Therefore, we compared serum concentrations of CCL20, CXCL8, and CXCL10 in RRMS patients in relapse with their concentrations in healthy controls and explored the association of chemokines with clinical characteristics of the disease, and concentrations of anti-EBV antibodies in patients with relapsing-remitting MS (RRMS). Here, CCL20 is linked to relapsing-remitting multiple sclerosis.